Adalvo, in collaboration with Arphio, is proud to introduce Teduglutide, a groundbreaking treatment addressing the urgent unmet needs of patients with Short Bowel Syndrome (SBS).
Short Bowel Syndrome is a rare disease characterized by the inability of the small intestine to absorb nutrients and fluids properly, leading to significant challenges for patients in maintaining adequate nutrition and hydration. Unfortunately, there are currently no approved treatments available for this debilitating condition apart from Teduglutide.
Teduglutide represents a first-to-file / first-to-market opportunity in the rare disease segment, offering new hope for patients affected by SBS. With no alternative pharmaceutical care indicated for SBS at the moment, the medical community and patients are eagerly anticipating the availability of this critical treatment.
The brand sold approximately $270Mn globally in 2022, having a significant growth potential with Global 3Y CAGR at +9%, according to IQVIA.
The unmet medical need for patients with Short Bowel Syndrome is enormous, and Teduglutide presents a unique opportunity to make a significant impact on their lives. Adalvo and Arphio are proud to offer this highly complex peptide injectable product, which holds the promise to improve the quality of life for patients living with Short Bowel Syndromes
Our partnership with Arphio to bring Teduglutide to the market underscores our dedication to transforming lives. Short Bowel Syndrome is a challenging condition, and Teduglutide offers a ray of hope to those affected. At Adalvo, we are committed to pioneering solutions that make a real difference in the lives of patients
The ongoing collaboration between Adalvo and Arphio ensures a clearly outlined intellectual property pathway, securing the delivery of this transformative treatment to those who need it most.
As Adalvo and Arphio continue their dedicated efforts toward Teduglutide's availability, they reiterate their commitment to patients and healthcare professionals alike. Aiming to ensure that this life-changing therapy reaches all eligible patients worldwide, addressing the significant unmet need in the treatment of SBS.